Global Cell and Gene Therapy CDMO Market Size & Trends Report Segmented by Service Type (Clinical Development, Commercial Manufacturing), Product Type (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication & Regional Forecast to 2030
The global cell and gene therapy CDMO market is anticipated to witness a CAGR of ~27% during the forecast period, driven by the growing burden of cancer and other targeted diseases, rapidly expanding research on cell and gene therapies and robust CGT pipeline, substantial funding by venture capitalists, and technological innovations. To learn more about the research report, download a sample report.
Report Overview
The development and approval of CAR-T cell therapies, such as Kymriah and Yescarta and their success in combating hematological malignancies have boosted investment in CGT. A robust CGT pipeline with a growing number of product approvals, strong support from large pharma and biotech, and consistent investor interest is set to boost the demand for CGT services. Also, a growing pipeline of therapies is nearing regulatory decisions. Additionally, CGT's reach is expanding across new indications. For instance, newer CAR-T therapies like Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), which were initially approved for multiple myeloma, are indeed expanding their indications beyond B-cell cancers.
To learn more about this report, download the PDF brochure
Growing demand for full-service/one-stop-shop CDMOs
Full-service CDMOs that can assist with both development and manufacturing are in high demand. Much of the gene therapy development has come from smaller biotech companies or research universities that rely on CDMOs from preclinical development through packaging. Big pharma and biopharma companies also prefer a full-service CDMO to speed up the timeline and free up resources to focus on innovation and marketing.
“There is growing demand for cell and gene therapy CDMOs who can offer integrated development, manufacturing, and testing services. For cell and gene therapy companies, outsourcing manufacturing and testing operations to a capable CDMO can reduce development timelines, provide supplementary capacity, and ultimately control costs.”- Senior Director, Tier 1 CGT CDMO, US
Greater focus on long-term strategic collaborations
The cell and gene therapy industry has witnessed a multi-fold rise in the number of collaborations between manufacturers/innovators and CDMOs in the form of joint ventures, manufacturing agreements, licensing agreements, service alliances, etc. For instance,
- In April 2025, Cell Therapies Pty Ltd and Xellera Therapeutics entered into a strategic partnership to accelerate the development and accessibility of cell and gene therapies across the Asia-Pacific region, focusing on expanding CGT access in Australia and Hong Kong through enhanced GMP manufacturing capabilities and collaborative innovation
- In October 2024, CytoImmune, a Biotechnology Company, established a strategic partnership with Matica Bio, a CDMO specializing in viral vectors, wherein Matica Bio will produce viral vectors at its GMP facility, and CytoImmune will manufacture its cell therapy in Puerto Rico, aiming to advance a clinical cell therapy program for cancer treatment
To learn more about this report, download the PDF brochure
Substantial outsourcing in the CGT industry due to lack of internal capabilities
Cell and gene therapy is a highly specialized area that requires substantial production investments, advanced infrastructure, and highly skilled professionals. Many large pharmaceutical companies, despite their scale, often lack the ready-to-go infrastructure and technical setups required to manage these therapies internally. As a result, they turn to specialized CDMOs to assist them in the development and manufacturing of CGT therapies. Additionally, the surge in the number of small biotech companies entering the market without having their advanced manufacturing facility and technical expertise has further amplified the reliance on CDMOs. With only a limited number of CGT-focused manufacturers in the market, the gap between demand and supply has created a strong growth opportunity for CDMOs with specialized CGT capabilities.
North America is the largest and fastest growing region
North America is the largest and fastest-growing cell & gene therapy (CGT) CDMO market. It is expected to continue its leadership in the coming 5 years owing to growing manufacturing capacity for CGTs, favorable regulatory approval process, growing cell and gene therapy approvals per year, and strong product pipeline of CGTs in the U.S. The regulatory approval process in the US is evolving and becoming favorable for innovators for developing cell and gene therapy products. The US FDA is designating orphan drug status, breakthrough designation, accelerated approvals, and regenerative medicine advanced therapy (RMAT) designations for cell and gene therapies to expedite the approval process.
Competitive Landscape Analysis
The cell & gene therapy (CGT) CDMO market is marked by the presence of both established players and several small and mid-sized players. Some of the key players in the market include Lonza, Catalent, Inc. (acquired by Novo Holdings), Cytiva (Danaher Corporation), Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, Charles River Laboratories, AGC Biologics, OmniaBio, Rentschler Biopharma SE, and WuXi AppTec, among several others.
Report Scope
Report Metric |
Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 – 2024 |
| Forecast Period | 2025 – 2030 |
| Growth Rate | ~27% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Service Type, Product Type, and Indication |
| Regional Scope |
|
| Key Companies Mapped | Lonza, Catalent, Inc. (acquired by Novo Holdings), Cytiva (Danaher Corporation), Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, Charles River Laboratories, AGC Biologics, OmniaBio, Rentschler Biopharma SE, and WuXi AppTec, among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Cell and Gene Therapy CDMO Market Segmentation
This report by Medi-Tech Insights provides the size of the global cell and gene therapy CDMO market at the regional- and country-level from 2023 to 2030. The report further segments the market based on service type, product type and indication.
Market Size & Forecast (2023-2030), By Service Type, USD Million
- Clinical Development
- Commercial Manufacturing
Market Size & Forecast (2023-2030), By Product Type, USD Million
- Gene Therapy
- Ex-vivo
- In-vivo
- Cell Therapy
- Gene-Modified Cell Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
Market Size & Forecast (2023-2030), By Indication, USD Million
- Oncology
- Neurological Disorders
- Infectious Diseases
- Rare Diseases
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the cell and gene therapy CDMO market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the cell and gene therapy CDMO market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Cell and Gene Therapy CDMO Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Growing demand for full-service/one-stop-shop CDMOs
- Advancements in gene editing and delivery technologies
- Rising demand for cell and gene therapies
- Growing investment in biopharma R&D
- Expanding pipeline of cell and gene therapies in clinical trials
- Restraints
- Complex regulatory landscape
- High manufacturing complexity and cost
- Limited skilled workforce
- Opportunities
- Substantial outsourcing in CGT industry
- Innovative partnerships and collaborations
- Expansion into emerging markets
- Development of allogeneic (off-the-shelf) therapies
- Key Market Trends
- Increased use of automation and digital manufacturing
- Focus on viral vector production
- Integration of end-to-end services
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Service Type, USD Million
- Introduction
- Clinical Development
- Commercial Manufacturing
- Global Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Product Type, USD Million
- Introduction
- Gene Therapy
- Ex-vivo
- In-vivo
- Cell Therapy
- Gene-Modified Cell Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- Global Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Indication, USD Million
- Introduction
- Oncology
- Neurological Disorders
- Infectious Diseases
- Rare Diseases
- Others
- Global Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Canada
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- US
- Europe Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Germany
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- France
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Italy
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Spain
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Europe
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- UK
- Asia Pacific (APAC) Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Japan
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- India
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- China
- Latin America (LATAM) Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Middle East & Africa (MEA) Cell and Gene Therapy CDMO Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Service Type (USD Million)
- Market Size & Forecast, By Product Type (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2025)
- New Product & Service Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Lonza
- Catalent, (acquired by Novo Holdings)
- Cytiva (Danaher Corporation)
- Samsung Biologics
- Thermo Fisher Scientific Inc.
- Novartis AG
- Charles River Laboratories
- AGC Biologics
- OmniaBio
- Rentschler Biopharma SE
- WuXi AppTec
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Biotechnology and Pharmaceutical Companies, Academic & Research Institutes and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
